Nosaki K, et al. - Researchers sought to analyze the safety and efficacy of pembrolizumab (a programmed death 1 inhibitor) in elderly patients (≥ 75 years) with advanced non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1)–positive tumors. From the KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894) studies, they included 264 elderly patients with advanced NSCLC with PD-L1–positive tumors. Randomization of patients to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or docetaxel, as second- or later-line therapy, was done in KEYNOTE-010. Randomization of patients to first-line pembrolizumab 200 mg Q3W or platinum-based chemotherapy was done in KEYNOTE-024 and KEYNOTE-042. Outcomes of this pooled analysis suggest that pembrolizumab vs chemotherapy resulted in improved overall survival, with a more favorable safety profile. Patients ≥ 75 years had comparable outcomes with pembrolizumab when compared with those in the overall populations in the individual studies.